BCL2 and B-cell chronic lymphocytic leukemia: However, as BCL2 inhibitors are nowadays mainly used as a time limited therapy in combination with CD20 antibodies and resistance mutations are not observed in relapsed patients but only in CLL refractory to continuous treatment, a diagnostic testing for such variants is only justified in special situation.